2017
Current and future pharmacologic treatment of nonalcoholic steatohepatitis
Banini BA, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current Opinion In Gastroenterology 2017, 33: 134-141. PMID: 28346237, PMCID: PMC5491795, DOI: 10.1097/mog.0000000000000356.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseEnd-stage liver diseaseNonalcoholic steatohepatitisLiver diseaseTrend of NAFLDChemokine receptor type 2Future pharmacologic treatmentsCornerstone of therapyStage liver diseaseFatty liver diseasePeroxisome proliferator activator receptorProgression of fibrosisAnti-inflammatory agentsDietary caloric restrictionGlucagon-like peptide 1 pathwayReceptor type 2Liver histologyMetabolic endotoxemiaPharmacologic treatmentTherapeutic optionsHepatocellular cancerAntifibrotic agentsIntestinal microbiomeAggressive formPharmacologic target
2016
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016, 65: 1049-1061. PMID: 26997538, PMCID: PMC4931958, DOI: 10.1016/j.metabol.2016.02.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCCAAT/enhancer-binding homologous proteinNonalcoholic fatty liver diseasePKR-like ER kinaseFatty liver diseaseP53 upregulated modulatorEndoplasmic reticulum stressGlucose intoleranceHepatocellular injuryPharmacological therapyLiver diseaseMetabolic derangementsInsulin resistanceHepatocyte injuryLipotoxic stateC-Jun NH2-terminal kinase 1Exposure of hepatocytesHigh fructoseProtective roleEnergy homeostasisUpregulated modulatorGlucose dietLipotoxicityMitochondrial impairmentOxidative stressReticulum stress